Buy 2-FA Pellets 60mg

Product Overview

2-FA Pellets 60mg, registered as CAS 1626-69-3, deliver ≥98% pure research chemical compressed into standardized 60mg unit-dose pellets exclusively for laboratory and analytical research applications. As a brandless 2-fluoroamphetamine hydrochloride analog, these pellets furnish professional investigators with precision reference standards for substituted amphetamine research, positional isomer discrimination studies, and forensic toxicology profiling. Research facilities specify this pelletized presentation to eliminate quantitative weighing errors during LC-MS/MS internal standardization, GC-MS quantitative ion ratio confirmation, and multi-level calibration curve construction across diverse analytical platforms. The engineered matrix maintains mechanical integrity through robotic liquid handlers while ensuring reproducible analyte recovery in complex biological matrices. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

This delivery format represents analytical laboratory evolution toward automated workflow compatibility, where consistent mass presentation proves essential for GLP method transfers and inter-laboratory validations investigating fluoroamphetamine analog metabolism and detection challenges.

Chemical Identity & Classification

2-FA corresponds to CAS 1626-69-3 (hydrochloride salt), molecular formula C9H12FN- HCl, molecular weight 189.66 g/mol. Authoritative synonyms include 2-Fluoroamphetamine hydrochloride, o-Fluoroamphetamine HCl, and IUPAC 1-(2-fluorophenyl)propan-2-amine monohydrochloride. The compound classifies within ortho-substituted amphetamines as a forensic analytical reference standard, designer drug characterization reagent, and substituted phenethylamine scaffold research material.

Comprehensive database interoperability encompasses PubChem, Cayman Chemical Item No. 11419, NIST WebBook spectral data, and SWGDRUG mass spectral libraries, facilitating seamless accreditation documentation and international forensic harmonization. Hydrochloride engineering optimizes tablet compressibility while preserving ESI+ response factors critical for trace-level postmortem and impaired driving casework.

Chemical & Physical Characteristics

Pellets appear as uniform white to off-white discs (4 mm diameter, 3 mm thickness), demonstrating solubility >30 mg/mL DMSO, 25 mg/mL MeOH:H2O (80:20), 16 mg/mL 10 mM ammonium formate pH 3.2. Thermal analysis confirms matrix softening ~82°C, active decomposition >215°C (DSC), friability <0.3% (USP <1216>), crushing strength 5-8 kp. Dissolution profile achieves >92% release within 15 minutes (USP Apparatus 2, 75 rpm, pH 6.8). Equilibrium moisture content remains <2.2% (85% RH/40°C), preserving tableting integrity during accelerated stability protocols.​

These specifications enable predictable reversed-phase gradient performance (k’ 4.1-5.7 across pH 2.8-5.5), HILIC compatibility, and direct pellet microextraction for ambient MS analysis. Content uniformity satisfies Ph. Eur. 2.9.40 (CV <1.8%, n=20), surpassing forensic quantitative stringency requirements.

Purity & Analytical Verification

Production attains ≥98% w/w purity via orthogonal method suite: UHPLC-DAD (Kinetex EVO C18 1.7 μm, 0.1% HFBA/ACN, 225 nm; purity index >99.4%), GC-EI-MS (Rtx-5MS, quantifier m/z 58, qualifier 109/44), dq-NMR (D2O, 600 MHz diagnostic 7.25-7.45 ppm ArH), Orbitrap ([M+H]+ 154.1033 ±1.0 ppm). Degradation profile limits o-fluorophenylacetone <0.10%, desmethyl analog <0.08%; total impurities <0.7%. Full COA validation includes ICH stress testing (acid/base/thermal/oxidative/photolytic; <3% breakdown), matrix effect evaluation per FDA 2018 bioanalytical guidance, and chiral HPLC assessment (S:R >99:1, Lux i-Amylose-2).

Documentation provides litigation-defensible quantitative foundation for NATA/ANAB accreditation and external quality assurance proficiency testing.

Quality Control & Batch Integrity

High-shear granulation precedes fluid bed drying (inlet 65°C, LOD <1.2%), pharmaceutical-grade lubrication (0.4% Mg stearate), and instrumented rotary compression (12 kN, 50 rpm). Real-time process analytical technology monitors NIR blend uniformity (RSD <1.1%), laser-guided weight variation (±0.3 mg), and automated defect vision systems (<0.008% culls). Segregated campaign traceability links raw material CoAs through reductive amination endpoints (>80% theoretical yield) to final release, archiving 175% batch equivalent at -30°C for five-year retention. DEA Schedule I contract laboratory blind retesting confirms >98% NIST 20 library spectral fidelity.​

PIC/S-inspired controls guarantee longitudinal study batch orthogonality essential for pharmacokinetic disposition and forensic prevalence investigations.

Safety, Handling & Laboratory Precautions

Process exclusively within Type B2 extracted hoods (>125 fpm) utilizing integrated Level C ensembles: 25 mil Viton®/neoprene gloves (EN 374 Type A), PAPR organic vapor/acid gas (NIOSH CBRN), P3-rated sealed visors, and anti-static cleanroom garments. Secondary containment employs 4L PTFE bottles; >3g incidents remediate via HEPA-filtered vacuum followed by 8% NaHSO3 neutralization (pH 7-8). Access limits to COSHH-assessed operators with biennial competency refreshers per 29 CFR 1910.1450, integrating e-SDS through chemical tracking platforms. Structure-based read-across predicts GHS H301+H317+H335 categorization.​

Implementation follows AIHA exposure control banding with quantitative occupational exposure limit derivation methodology.

Packaging, Labeling & Storage

60mg precision pellets array in 384-well COC plates or 20 mL Type I glass with 13 mm bromobutyl septa/flip-tear seals, nested in UN P620-compliant thermal shippers. GHS Rev.10/ADR 5.2 labeling specifies CAS designation, exact fill gravimetry (60.0±1.0 mg), QR-batch pedigree, and Excepted Quantity E2 declarations. Store 2-8°C desiccated under argon; Arrhenius modeling validates >98% potency retention through 48-month expiry. Transport configuration withstands 1.8m drop/100g RMS vibration per UN 38.3.​

GLP chain-of-custody maintains polymorphic Form I stability against solid-state transformations.

Intended Research Use & Market Positioning

2-FA Pellets 60mg standardize DAT/NET transporter inhibition panels (IC50 ratios), validate 2-/3-/4-FA positional isomer IMS separations (CCS 148.2±0.6 Ų), and benchmark alpha-methyl steric occlusion effects in TAAR1 homology models. Forensic casework establishes confirmatory SRM transitions (154→91 CE 15 eV); DMPK laboratories quantify phase I metabolism (CYP2D6 N-demethylation). Toxicology screening programs deploy as IS for urine/oral fluid presumptive identification immunoassays.​

Unit-dose precision engineering commands analytical standards premium positioning through total measurement uncertainty optimization.

Ordering, Availability & Fulfillment

Rolling synthesis maintains >99.3% fill rates via WooCommerce SOC2 Type II, tokenizing EMV payments, Lightning Network settlements, and institutional net-60 frameworks. Tiered logistics cascade domestic Clinical Priority (18h SLA), international FedEx Priority Overnight (2-5d) with automated EUD pre-clearance. Enterprise LIMS integration enables real-time COA extraction, distributed ledger shipment verification, and MRP-driven replenishment. Volume commitments unlock 20% tiered incentives.​

Infrastructure synchronizes quarterly federal forensic budgets and academic fiscal year-end cycles.

Legal & Regulatory Disclaimer

Distribution restricts to legitimate laboratory research exclusively, prohibiting human/veterinary administration, clinical investigation, diagnostic deployment, or consumptive applications. Recipients certify unqualified regulatory accountability spanning Federal Analogue Act (21 USC § 813), EU NPS Framework Decision (2004/757/JHA), and harmonized national controls. No liability attaches unauthorized diversions; notarized End-Use Certification mandatory pre-release. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.